KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Depreciation & Amortization (CF) (2017 - 2025)

Teva Pharmaceutical Industries' Depreciation & Amortization (CF) history spans 9 years, with the latest figure at $260.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 3.35% year-over-year to $260.0 million, compared with a TTM value of $1.0 billion through Dec 2025, down 5.19%, and an annual FY2025 reading of $1.0 billion, down 5.38% over the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $260.0 million at Teva Pharmaceutical Industries, up from $249.0 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $376.0 million in Q1 2021, with the low at $244.0 million in Q1 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $292.7 million, with a median of $291.5 million recorded in 2023.
  • Year-over-year, Depreciation & Amortization (CF) decreased 20.16% in 2021 and then grew 17.38% in 2022.
  • Tracing TEVA's Depreciation & Amortization (CF) over 5 years: stood at $320.0 million in 2021, then dropped by 4.38% to $306.0 million in 2022, then fell by 13.07% to $266.0 million in 2023, then increased by 1.13% to $269.0 million in 2024, then dropped by 3.35% to $260.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Depreciation & Amortization (CF) are $260.0 million (Q4 2025), $249.0 million (Q3 2025), and $251.0 million (Q2 2025).